About Bio pharmazeutika werden
The new generation of biotechnological medicines which are typically created from living cells, are revolutionizing the way the medical conditions are treated. In contrast to traditional small molecule medicines that use chemicals, bio pharmazeutika werden are manufactured from a wide spectrum of complex biological substances and are intended to treat a range of diseases that have not been adequately addressed by conventional medications based on small molecules alone.
Biopharmazeutika werden are produced using gentechnische production (GTP) from in cultured bacteria, mammalian cells such as the popular CHO-Zellen, or even plants, which can be cultivated using plant biotechnology (Pflanzenbiotechnologie). Contrary to conventional drugs that are made in the lab using chemical processes All bio pharmazeutika are produced by living organisms and therefore must be identified by their unique atom-by-atom structure.
Due to their complexity bio pharmazeutika werden cannot be reproduced precisely by chemical experts. Therefore, they are referred to as biosimilars and not generics. When the patent protection of an original medication expires, companies are able to develop their own versions of the drug to sell, as long as they comply with specific statutory requirements which are known as Biosimilar Guidelines.
Biopharmazeutika can be taken directly or as a component https://genotec-frankfurt.de/bio-pharmazeutika-werden-zu-einer-anerkannten-form-der-alternativmedizin/ in the manufacture of a wide range of therapeutic devices such as polysaccharides and peptides. These substances are recombined in the downstream processing of Biopharmazeutika to make complex biologic drugs. Recombinant biopharmazeutika is comprised of insulin, interleukin, and monoclonal antibody.